{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:24:38Z","timestamp":1794003878704,"version":"4.8.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejca.2026.117064","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:51:32Z","timestamp":1790265092000},"page":"117064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?"],"prefix":"10.1016","volume":"248","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1199-0153","authenticated-orcid":false,"given":"Vitor T.","family":"Liutti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-7837","authenticated-orcid":false,"given":"Hans","family":"Wildiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8088-9628","authenticated-orcid":false,"given":"Gabe S.","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1434-9460","authenticated-orcid":false,"given":"Patrick","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.117064_bib1","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk, Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100\u2008000 women from 86 randomised trials. Lancet. 2023;401:1277\u20131292."},{"key":"10.1016\/j.ejca.2026.117064_bib2","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37\u2008298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393:1440\u20131452."},{"key":"10.1016\/j.ejca.2026.117064_bib3","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-26-520834","article-title":"Personalizing Curative Therapy in Stage II to III triple-negative breast cancer","volume":"46","author":"LeVee","year":"2026","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejca.2026.117064_bib4","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117064_bib5","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMc2416491","article-title":"Pembrolizumab in early-stage triple-negative breast cancer","volume":"392","author":"Neven","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117064_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.507","article-title":"Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study","volume":"44","author":"Schmid","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117064_bib7","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.117064_bib8","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III Melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117064_bib9","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117064_bib10","doi-asserted-by":"crossref","first-page":"S1600","DOI":"10.1016\/j.annonc.2025.09.069","article-title":"LBA57 two-year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma","volume":"36","author":"Lucas","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117064_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.1285","article-title":"Neoadjuvant-adjuvant vs neoadjuvant-only PD-1 and PD-L1 inhibitors for patients with resectable NSCLC: An Indirect Meta-Analysis","volume":"7","author":"Zhou","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2026.117064_bib12","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO-25-02311","article-title":"Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer: long-term analysis from the GeparNuevo Trial","volume":"44","author":"Loibl","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117064_bib13","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jama.2024.26886","article-title":"Adjuvant Atezolizumab for early triple-negative breast cancer: The ALEXANDRA\/IMpassion030 randomized clinical trial","volume":"333","author":"Ignatiadis","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2026.117064_bib14","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.annonc.2025.08.005","article-title":"A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients","volume":"36","author":"Conte","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117064_bib15","unstructured":"Park et al. Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)."},{"key":"10.1016\/j.ejca.2026.117064_bib16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jamaoncol.2024.3456","article-title":"Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: a systematic review and meta-analysis","volume":"10","author":"Villacampa","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.117064_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2024.6809","article-title":"Long-term toxicity of immune checkpoint inhibitors-time to widen the lens","author":"Cronin","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.117064_bib18","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.117064_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27145","article-title":"Extended follow-up of chronic immune-related adverse events following adjuvant anti-PD-1 Therapy for High-Risk Resected Melanoma","volume":"6","author":"Goodman","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2026.117064_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006500","article-title":"Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review","volume":"11","author":"Barron","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.117064_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104473","article-title":"Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real\/GBECAM 0123 study","volume":"83","author":"Andrade","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2026.117064_bib22","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/jnci\/djae129","article-title":"Neoadjuvant pembrolizumab plus chemotherapy\/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study","volume":"116","author":"Dent","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.117064_bib23","doi-asserted-by":"crossref","first-page":"e915","DOI":"10.1016\/S2542-5196(24)00245-6","article-title":"Effect of alternative dosing strategies of pembrolizumab and nivolumab on health-care emissions in the Netherlands: a carbon footprint analysis","volume":"8","author":"Malmberg","year":"2024","journal-title":"Lancet Planet Health"},{"key":"10.1016\/j.ejca.2026.117064_bib24","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-LB1-07","article-title":"Abstract LB1-07: Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage TNBC","volume":"31","author":"O\u2019Shaughnessy","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.117064_bib25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/jamaoncol.2025.5376","article-title":"Enhancing clinical cancer research through sharing of data and biospecimens","volume":"12","author":"Wildiers","year":"2026","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.117064_bib26","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-GS3-05","volume":"31","author":"Geyer","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.117064_bib27","volume":"32","author":"Balic","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.117064_bib28","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS25-RF3-02","article-title":"Abstract RF3-02: gene expression-based subtyping of early triple-negative breast cancer (TNBC) for prediction of response to neoadjuvant immune-chemotherapy in the NSABP B-59\/GBG-96-GeparDouze Trial","volume":"32","author":"Denkert","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.117064_bib29","first-page":"2885","article-title":"The prognostic significance of TILs as a biomarker in triple-negative breast cancer: what is the role of TILs in TME of TNBC?","volume":"25","author":"Zhou","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:33:07Z","timestamp":1794000787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926008464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":29,"alternative-id":["S0959804926008464"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117064","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117064"}}